Wetherby Asset Management Inc Ultragenyx Pharmaceutical Inc. Transaction History

Wetherby Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$45.8 - $85.4 $232,709 - $433,917	-5,081 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$62.2 - $84.4 $7,775 - $10,550	125 Added 2.52%	5,081 $369,000
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $15,036 - $17,923	204 Added 4.29%	4,956 $417,000
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $389 - $512	-5 Reduced 0.11%	4,752 $429,000
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $438,547 - $550,432	4,757 New	4,757 $454,000
Q1 2021 May 14, 2021	SELL	$106.9 - $167.73 $507,668 - $796,549	-4,749 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$72.98 - $90.0 $346,582 - $427,410	4,749 New	4,749 $390,000

325

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.07B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Wetherby Asset Management Inc with notifications on news.